Cyclohexyl peptides as selective somatostatin SST5 receptor agonists
By developing cyclohexene peptide compounds with selective type 5 somatostatin receptor agonist, the problem of insufficient development of SST5 agonist in the prior art was solved, and efficient activation and therapeutic effect of SST5 was achieved, especially in the pituitary gland. It has significant therapeutic effects in the treatment of diseases such as neuroendocrine tumors.
Patent Information
- Application Number
- CN202411113093.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2018-10-12
- Filing Date
- 2019-10-14
- Publication Date
- 2024-11-08
AI Technical Summary
The existing somatostatin receptor agonists have insufficient selectivity and poor efficacy in the treatment of diseases such as pituitary and neuroendocrine tumors, especially the lack of agonists for the type 5 somatostatin receptor (SST5) .
A new class of cyclohexane peptide compounds have been developed as selective type 5 somatostatin receptor (SST5) agonists, which significantly improves the affinity and selectivity for SST5 through specific chemical structure design.
These compounds can effectively activate SST5 receptors, providing higher therapeutic selectivity and efficacy, especially in the treatment of SST5-related diseases such as Kuxing's disease, acromegaly, neuroendocrine tumors. Secretion and antiproliferative effects.
Smart Images

Figure CN118909047A_ABST
Abstract
Description
[0001] This application is filed on October 14, 2019, with application number 201980082823.4, and the name of the invention is “Selective somatostatin SST 5 A divisional application of the application entitled "Cyclohexyl peptide as a receptor agonist".
[0002] The present invention relates to a class of novel cyclic peptide compounds, their salts, pharmaceutical compositions containing them and their use in the treatment of human body. In particular, the present invention relates to a class of compounds as agonists of somatostatin receptor (SST). More particularly, the present invention relates to compounds as agonists of somatostatin receptor type 5 (SST). 5 The present invention also relates to the manufacture of these compounds and compositions and their use in preventing or treating such diseases in which somatostatin receptors are involved. Background of the Invention
[0004] Somatostatin is a ubiquitous cyclic polypeptide hormone that binds to somatostatin receptor subtypes 1-5 (SST 1-5 ) to exert its physiological function. Two biologically active forms of somatostatin, called somatostatin-14 and somatostatin-28 based on their amino acid chain length, are derived from a 92-amino acid precursor protein and show different SST selectivity profiles. Although somatostatin-14 has a strong affinity for SST, it has a strong affinity for SST. 1-4 It has a higher binding affinity, but somatostatin-28 has a lower affinity for SST 5 The hypothalamus is the major site of somatostatin production in the central nervous system, and the hypophyseal portal system allows direct access to the pituitary gland, where SST 1 、SST 2 、SST 3 and SST 5 The expression of somatostatin-14 has been confirmed. Somatostatin-14 can act on different pituitary cell types including somatotrophs and adrenocorticotrophs and regulate the secretion of hormones such as growth hormone (GH) and adrenocorticotrophic hormone (ACTH), respectively. In addition, somatostatin is also synthesized in peripheral areas such as the mucous membranes of the gastrointestinal tract and pancreatic islets, where somatostatin can regulate the secretion of local hormones in an autocrine and / or paracrine manner.
[0005] These five SST subtypes belong to the G protein-coupled receptor (GPCR) superfamily and were cloned as mediators of somatostatin-dependent effects in independent studies in 1992. 2 、SST 2A and SST 2B Two splice variants of SST have been identified in mouse brain regions including the cortex, hippocampus, striatum, and hypothalamus and encode 2B Transcripts of SST have also been found in tissue isolated from human growth hormone adenomas. 5 Several isoforms are also expressed in humans that are functional despite deletion of two or three transmembrane domains due to cryptic splice sites. Expression of SST has been demonstrated in a variety of tissues consistent with the functional activity of somatostatin. Anatomical profiling of GPCR expression in mice has highlighted the expression of all SST isoforms in multiple brain regions including the hippocampus, hypothalamus, and pituitary gland; however, in the periphery, SST 2 appears to be the predominantly expressed SST isoform. In healthy human tissues, SST is similarly distributed with respect to the expression of all isoforms in the brain and the expression of selected isoforms in peripheral organs, such as SST 1-3 In the eye, SST 1 In the stomach and kidneys, SST 1-3 and SST 5 In the pancreas, and SST 5 In the pituitary gland. Multiple independent studies have also identified the expression of SST mRNA and protein in several human tumors, including pituitary tumors, neuroendocrine tumors, renal cell carcinoma, breast cancer, meningioma, glioma, neuroblastoma, and colorectal cancer. The ability of SST to attenuate hormone secretion provides a potential strategy for therapeutically managing enhanced tumor secretory activity. In addition, a large body of evidence has highlighted that SST signaling also has antiproliferative effects on tumor cells.
[0006] The main molecular mechanism of SST activity is based on their interaction with G proteins. i The ability of SST to couple with isoforms has an inhibitory effect on adenylate cyclase and thus leads to inhibition of cAMP production. In addition, SST has the ability to affect ion channel signaling; the activation of SST is related to K + Channel activation and Ca 2+These signaling cascades triggered by SST agonists lead to inhibition of exocytosis, which forms the basis for their inhibitory effect on hormone secretion. Another signaling output of SST activation, particularly for those receptors present on tumor cells, is the inhibition of proliferation, which is mainly mediated by G2 binding to protein tyrosine phosphatases such as SHP-1 and SHP-2. i Various SSTs have been shown to attenuate growth factor receptor signaling and downregulate the synthesis of growth factors such as growth hormone (GH) and insulin-like growth factor 1 (IGF-1), block cell cycle progression, inhibit angiogenesis (possibly by blocking nitric oxide synthase activity), and activate apoptosis-inducing pathways that are also involved in regulating cell adhesion and motility, such as Na + / H + Inhibition of exchange.
[0007] SST agonists have therapeutic potential in a range of pituitary disorders as there is a large body of evidence supporting the hypothesis that SST agonists may be beneficial in the treatment of pituitary tumors. SST expression has been demonstrated in pituitary tumors and although upregulation and / or downregulation of specific SST isoforms appears to be variable and dependent on tumor subtype and individual patient, in most cases SSTR2 and SSTR5 appear to be present. In addition, SST agonists have antisecretory effects on both healthy and cancerous pituitary gland tissue, including somatotroph and corticotroph adenomas. Available somatostatin analogs, first generation SST 2 The selective agonists octreotide and lanreotide and the second-generation multi-receptor agonist pasireotide have demonstrated efficacy in the treatment of a variety of disorders caused by pituitary adenomas. Long-acting release (LAR) formulations of octreotide and lanreotide have been used successfully to treat acromegaly, a condition whose symptoms are associated with GH-secreting adenomas of the pituitary gland. A meta-analysis of 44 clinical studies showed that up to two-thirds of patients achieved biochemical control, as defined by normalisation of circulating GH and IGF-1 levels, following treatment with octreotide LAR, and tumour shrinkage was observed in half of the cases. Patients refractory to medical therapy or who were blocked by octreotide LAR were compared with the multi-receptor agonist pasireotide (pasireotide vs octreotide for SST) and had a significantly lower risk of developing acromegaly. 5 、SST 1 and SST 3Positive results were shown in the treatment of patients with acromegaly who were inadequately controlled with octreotide, with improved biochemical control and a significant increase in the response to SST 2 Selective agonist therapy is effective in patients resistant to it.
[0008] Somatostatin analogs are effective in treating Cushing's Disease, which is characterized by excessive secretion of ACTH. Based on the predominant expression of SSTR5 on corticotroph adenomas, pasireotide treatment of patients with Cushing's disease resulted in a significant reduction in cortisol levels and tumor shrinkage in a phase II trial. In addition, pasireotide treatment of patients with Cushing's disease resulted in a significant reduction in urinary free cortisol levels in a phase III trial. This was associated with significant improvements in disease-specific signs and symptoms such as: reduced blood pressure, a reduction in total cholesterol and low-density lipoprotein cholesterol, and a reduction in body mass index, weight, and waist circumference. In addition, pasireotide has been shown to reduce plasma ACTH levels in patients with Nelson's syndrome.
[0009] Selected cases have reported the ability of octreotide to inhibit thyroid stimulating hormone (TSH) secretion from pituitary thyrotropin tumors. The extent of octreotide efficacy appears to depend on the expression level of SSTR2 relative to SSTR5. In several preclinical studies, SST agonists have shown antisecretory effects on in vitro cultures of prolactin-secreting prolactinomas, and expression analysis of gonadotropin-releasing adenomas suggests that targeting SST 3 Instead of SST 2 Somatostatin analogs may be better than SST 2 Selective agonists are more effective.
[0010] In addition to pituitary adenomas showing clinical symptoms associated with hormone hypersecretion, SST agonists also have potential applications in the treatment of non-functioning pituitary adenomas. Administration of pasireotide reduces cell viability of non-functioning adenoma cultures in vitro by inhibiting the release of vascular endothelial growth factor, and pasireotide LAR is being evaluated in a phase II study to assess its efficacy and safety in the treatment of patients with clinically non-functioning pituitary adenomas.
[0011] Thus, selective SST agonists have potential utility in treating disorders associated with functional pituitary adenomas and altered pituitary hormone levels, such as levels of GH and associated excess IGF-1 (including but not limited to acromegaly and type I or II diabetes, particularly complications thereof, such as vasculopathy, diabetic proliferative retinopathy, diabetic macular edema, nephropathy, neuropathy and dawn phenomenon, and other metabolic disorders associated with insulin or glucagon release, such as treatment of morbid obesity, hypothalamic or hyperinsulinemic obesity), excess ACTH and Cortisol (including but not limited to treatment of Cushing's syndrome or Cushing's disease and related conditions such as Nelson's syndrome), disorders associated with excess prolactin (including but not limited to treatment of hyperprolactinemia), LH / FSH-secreting gonadotroph pituitary adenomas, TSH-secreting thyroid-stimulating hormone adenomas (including but not limited to thyrotropinomas and related conditions such as hyperthyroidism), and clinically non-functional pituitary adenomas.
[0012] The therapeutic benefits of the antisecretory and antiproliferative effects of SST agonists have also been demonstrated in other types of cancer, such as neuroendocrine tumors (NETs), which are produced by neuroendocrine cells present in a wide range of tissues and are characterized by excessive hormone secretion. Evaluation of SST expression across NETs of different tissue origin in independent studies showed that SSTR2 and SSTR5 were the most widely expressed subtypes, while SSTR1, SSTR3, and SSTR4 appeared to be more selectively expressed in specific tissues (Vitale et al., 2018). However, it is possible that, similar to pancreatic tumors, the expression of the corresponding SST subtypes will vary between individuals. The first-line therapy for NETs is surgical intervention with the goal of complete resection, however, in independent preclinical and clinical studies, SST agonists have shown efficacy in the therapeutic management of unresectable NETs. Treatment with the first generation SST agonist lanreotide and the second generation SST agonist pasireotide has been shown to alleviate the symptoms of carcinoid syndrome, which is caused by carcinoid tumours, a type of slow-growing NET that most often occurs in the gastrointestinal tract. In addition, pasireotide LAR alone or in combination with everolimus showed evidence of anti-tumor activity and the potential for improving progression-free survival in a phase II trial of medullary thyroid carcinoma and in carcinoid tumours of lung and thymus origin. In addition to NET, pasireotide has also shown clinical benefit in the treatment of non-neuroendocrine tumors, which resulted in limited disease progression in 45% of patients in a phase II trial of hepatocellular carcinoma, and a 68% disease control rate using combination therapy with gemcitabine in a phase I trial of pancreatic cancer.
[0013] Thus, selective SST agonists, used alone or in combination with other therapeutic agents, have potential utility in the treatment of tumors and related disorders, including, but not limited to, skin cancer (e.g., metastatic melanoma and Merkel cell carcinoma), lung cancer (e.g., small cell lung cancer and non-small cell lung cancer, including adenocarcinoma and squamous cell cancer), liver cancer (e.g., hepatocellular carcinoma), pancreatic cancer, gastrointestinal cancer, prostate cancer (including prevention of postoperative pancreatic fistula development following elective pancreatic resection), thymic cancer (e.g., thymoma and thymic carcinoma), and cancer of adrenal origin; neuroendocrine tumors; carcinoid tumors and related carcinoid syndromes.
[0014] Substantial evidence suggests that SST agonists will have therapeutic benefit in conditions associated with dysregulation of glucose homeostasis. Expression of SST has been demonstrated in endocrine cells of the pancreas, including glucagon-secreting alpha cells, insulin-secreting beta cells, and somatostatin-secreting delta cells. Expression of SSTR1, SSTR3, and SSTR4 has been demonstrated in all endocrine cell types of the human pancreas, whereas SSTR2 is more frequently expressed in alpha cells and beta cells, and SSTR5 is primarily expressed in beta cells and delta cells. Multiple independent preclinical studies have shown that SST 5 or SST 2 SSTRs are the major SSTRs that contribute to the inhibition of insulin secretion, and the target molecular mechanisms that achieve an optimal balance between inhibition of insulin and glucagon secretion are not fully understood. However, clinical evidence suggests that SSTR agonists are effective in treating conditions associated with elevated insulin levels and / or decreased blood glucose levels.
[0015] The LARs of octreotide and lanreotide have been successfully used to treat congenital hyperinsulinism (CHI), especially in patients who do not respond to diazoxide. The pan-selective SST agonist pasireotide is also currently being evaluated in the treatment of CHI. The long-acting properties of these preparations allow treatment to be reduced to monthly injections, which also greatly helps to improve the quality of life. Another condition that has shown therapeutic potential and leads to hyperinsulinemic hypoglycemia is post-gastric bypass hypoglycemia, which can be caused by dumping syndrome, nesidioblastosis and / or insulinoma. In independent case studies, octreotide and pasireotide treatment can control hypoglycemia. In addition, in a phase II trial, pasireotide was able to significantly reduce the incidence of hypoglycemia in dumping syndrome, which is one of the main causes of hypoglycemia after gastric bypass.
[0016] Therefore, selective SST agonists have potential utility in treating disorders associated with hyperinsulinemic hypoglycemia, including but not limited to congenital hyperinsulinism, post-gastric bypass hypoglycemia, and conditions that can lead to hypoglycemia, such as dumping syndrome, islet cell hyperplasia, and insulinomas.
[0017] Somatostatin also plays an important role in the retina, as it is one of the key neuroprotective factors produced by retinal pigment epithelial cells, and multiple SSTs are expressed in the retina, of which SSTR1 and SSTR2 are the most prevalent. Multiple mechanisms of action of somatostatin contribute to its neuroprotective properties, such as its ability to inhibit glutamate release, which is thought to contribute primarily to neurodegeneration through overexcitation of retinal glutamate receptors, and to attenuate the secretion of vascular endothelial growth factor, which can contribute to ischemic injury. Somatostatin analogs have shown efficacy in different ocular conditions; octreotide treatment over 3 years was able to reduce vitreous hemorrhage and led to improvements in visual acuity in patients with proliferative diabetic retinopathy; meta-analyses of clinical studies have demonstrated that octreotide shows efficacy in treating different stages of diabetic retinopathy and thyroid eye disease; and visual acuity has improved in some cases of cystoid macular edema after treatment with octreotide. Although pasireotide has not yet been tested in a clinical setting to evaluate its efficacy in eye-related disorders, preclinical studies have shown that pasireotide also has a neuroprotective effect in retinopathy.
[0018] Therefore, selective SST agonists have potential utility in treating eye-related disorders that would benefit from a neuroprotective agent, including, but not limited to, different types of diabetic retinopathy (eg, early and proliferative); macular edema; and thyroid eye disease.
[0019] There is new preclinical evidence that SST agonists may have therapeutic benefit in the treatment of polycystic kidney disease (PKD) and PKD-related cyst development in other organs, most commonly the liver. Since increased levels of cAMP in renal tubular epithelial cells have been associated with accelerated progression of PKD, activation of the Gi-dependent signaling pathway by SST agonists should have a beneficial effect. In fact, in a rat model of PKD, combined treatment with octreotide and pasireotide resulted in a reduction in kidney weight and renal cyst area, while the combination of pasireotide treatment with a histone deacetylase 6 inhibitor achieved a reduction in liver and kidney cyst growth in the same model system. There is also evidence that octreotide is beneficial in the treatment of polycystic ovary syndrome. Therefore, selective SST agonists have the potential to treat PKD and related cyst development in other organs, including but not limited to polycystic liver disease and polycystic ovary syndrome.
[0020] Preclinical and clinical evidence suggests that treatment with SST agonists results in a reduction in portal hypertension, a common complication of liver cirrhosis. Combination treatment with celecoxib and octreotide in a rat model of liver cirrhosis resulted in a reduction in portal hypertension by inhibiting angiogenesis, and in a clinical study comparing octreotide LAR treatment with placement of a transjugular intrahepatic portosystemic shunt (TIPS) in patients with portal hypertension, administration of octreotide was similarly effective as TIPS placement in reducing liver pressure. Therefore, selective SST agonists have the potential utility of treating portal hypertension and conditions (e.g., ascites) that may be caused by portal hypertension.
[0021] SST agonists may have therapeutic potential in the treatment of gastrointestinal disorders because of their ability to inhibit gastric acid secretion, exocrine and endocrine pancreatic secretion, and gastrointestinal peptide secretion. Therefore, selective SST agonists have potential utility in the treatment of gastrointestinal disorders, including but not limited to the treatment of peptic ulcers, enterocutaneous and pancreatic fistulas, irritable bowel syndrome and irritable bowel syndrome and disease, watery diarrhea syndrome, AIDS-related diarrhea, chemotherapy-induced diarrhea, acute or chronic pancreatitis, and gastrointestinal bleeding.
[0022] Some pain disorders may be amenable to treatment with selective SST agonists; octreotide has been used successfully to relieve pain in cancer patients for whom opioid analgesics do not provide adequate pain control, and acute treatment of cluster headache with octreotide resulted in significantly better pain relief than placebo. Thus, selective SST agonists may be useful in the treatment of pain disorders including, but not limited to, Headache disorders (e.g., migraine, cluster headache, and tension-type headache), neuropathic pain, hyperalgesia, causalgia, acute pain, burn pain, atypical facial pain, back pain, complex regional pain syndrome I and II, post-chemotherapy pain, post-stroke pain, post-operative pain, and other conditions associated with pain.
[0023] The present invention
[0024] The present invention provides compounds having activity as somatostatin receptor agonists. More particularly, the present invention provides compounds having activity as somatostatin receptor agonists with respect to somatostatin type 2 receptors (SST 2 ) of other somatostatin receptor subtypes, somatostatin type 5 receptor (SST 5 ) compounds that exhibit selectivity.
[0025] Therefore, in one embodiment, the present invention provides a compound of formula (1):
[0026]
[0027] or a salt thereof, wherein:
[0028] W is CH or N;
[0029] X and Y are CH 2 or O, wherein one of X and Y is CH 2 , and the other of X and Y is O;
[0030] Z is for CHR 7 NR 8 or O;
[0031] m is 1 or 2;
[0032] n is 0 to 3;
[0033] Each R 1 independently selected from halogen, C 1 -C 3 Alkyl and C 1 -C 3 Alkoxy, where C 1 -C3 Alkyl groups and C 1 -C 3 The alkoxy group is optionally substituted with up to 6 fluorine atoms;
[0034] q is 0 to 2;
[0035] R 2 is selected from H and C optionally substituted by up to 6 fluorine atoms 1 -C 3 alkyl;
[0036] R 3 is selected from optionally substituted C 1 -C 6 Alkyl, optionally substituted C 3 -C 6 cycloalkyl, optionally substituted aryl, and optionally substituted heteroaryl;
[0037] R 4 is H or optionally substituted C 1 -C 3 Alkyl, wherein the C 1 -C 3 The alkyl group is optionally attached to R 5 to form a ring;
[0038] R 5 is selected from optionally substituted C 1 -C 6 alkyl, optionally substituted aryl and optionally substituted heteroaryl, wherein R 5 Optionally connected to R 4 to form a ring;
[0039] R 6 is selected from optionally substituted aryl, optionally substituted heteroaryl, optionally substituted O-aryl or optionally substituted O-heteroaryl;
[0040] R 7 is selected from H, optionally substituted C 1 -C 6 Alkyl, CONR 10 R 11 、OCONR 10 R 11 ,OCOR 10 、OCOOR 10 、COOR 10 OR 12 ;
[0041] R 8 Selected from H, CONR 10 R 11or COOR 10 ;
[0042] R 10 and R 11 are independently selected from H, optionally substituted C 1 -C 6 Alkyl and optionally substituted C 2 -C 6 Alkyl, where C 2 -C 6 Any one atom in the alkyl group is replaced by a heteroatom selected from N, O and S, or wherein R 10 and R 11 are optionally linked to form a ring; and
[0043] R 12 is optionally substituted aryl or optionally substituted heteroaryl.
[0044] Specific compounds also include compounds of formula (1a):
[0045]
[0046] or a salt thereof, wherein W, X, Y, Z, m, n, q, R 1 , R 2 , R 3 , R 4 , R 5 and R 6 is as defined above.
[0047] Specific compounds also include compounds of formula (1b):
[0048]
[0049] or a salt thereof, wherein W, Z, m, q, R 1 and R 3 is as defined above.
[0050] The compounds herein can be used as somatostatin receptor type 5 (SST 5) agonists. The compounds can be used in the manufacture of drugs. The compounds or drugs can be used to treat, prevent, improve, control or reduce the risk of disorders associated with somatostatin receptors, including Cushing's disease, Cushing's syndrome, acromegaly, neuroendocrine tumors (including carcinoid tumors), thyrotropin tumors, prolactinomas, non-functional pituitary adenomas, Nelson's syndrome, congenital hyperinsulinemia, hypoglycemia after gastric bypass, dumping syndrome, hyperinsulinemic obesity, insulinoma, polycystic kidney disease, polycystic liver disease, portal hypertension, ascites, pancreatic cancer, pancreatic fistula, acute or chronic pancreatitis, hepatocellular carcinoma, irritable bowel syndrome / irritable bowel disease, headache disorders (including migraine, cluster headache, tension-type headache), islet cell proliferation, neuropathic pain, hyperalgesia, causalgia, acute pain, burn pain (Burn pain), atypical facial pain, back pain, complex regional pain syndrome types I and II, post-chemotherapy pain, post-stroke pain, postoperative pain, type I diabetes, type II diabetes, diabetic retinopathy, diabetic macular edema, thyroid eye disease, cystoid macular edema, diabetic nephropathy, diabetic neuropathy, peptic ulcer, enterocutaneous and pancreatic fistulas, watery diarrhea syndrome, AIDS-related diarrhea, chemotherapy-induced diarrhea, and gastrointestinal bleeding. DETAILED DESCRIPTION OF THE INVENTION
[0052] The present invention relates to novel compounds. The present invention also relates to novel compounds as SST 5 The present invention also relates to novel compounds for use as SST agonists. 5 The present invention also relates to a drug that is a selective SST 5 Receptor agonist compounds, compositions and medicaments.
[0053] The present invention also relates to compounds, compositions and medicaments useful for treating Cushing's disease, Cushing's syndrome, acromegaly, neuroendocrine tumors (including carcinoid tumors), thyrotropinomas, prolactinomas, non-functioning pituitary adenomas, Nelson's syndrome, congenital hyperinsulinism, hypoglycemia after gastric bypass, dumping syndrome, hyperinsulinemic obesity, insulinomas, polycystic kidney disease, polycystic liver disease, portal hypertension, ascites, pancreatic cancer, pancreatic fistula, acute or chronic pancreatitis, hepatocellular carcinoma, irritable bowel syndrome / irritable bowel disease, headache disorders (including migraine, cluster headaches, headache, tension-type headache), islet cell proliferation, neuropathic pain, hyperalgesia, causalgia, acute pain, burn pain, atypical facial pain, back pain, complex regional pain syndrome type I and II, post-chemotherapy pain, post-stroke pain, postoperative pain, type I diabetes, type II diabetes, diabetic retinopathy, diabetic macular edema, thyroid eye disease, cystoid macular edema, diabetic nephropathy, diabetic neuropathy, peptic ulcer, enterocutaneous and pancreatic fistula, watery diarrhea syndrome, AIDS-related diarrhea, chemotherapy-induced diarrhea, and gastrointestinal bleeding.
[0054] The compounds of the present invention include compounds of formula (1):
[0055]
[0056] or a salt thereof, wherein:
[0057] W is CH or N;
[0058] X and Y are CH 2 or O, wherein one of X and Y is CH 2 and the other of X and Y is O;
[0059] Z is CHR 7 NR 8 or O;
[0060] m is 1 or 2;
[0061] n is 0 to 3;
[0062] Each R 1 independently selected from halogen, C 1 -C 3 Alkyl and C 1 -C 3 Alkoxy, wherein the C 1 -C 3 Alkyl groups and C 1 -C 3 The alkoxy group is optionally substituted with up to 6 fluorine atoms;
[0063] q is 0 to 2;
[0064] R 2 is selected from H and C optionally substituted by up to 6 fluorine atoms 1 -C 3 alkyl;
[0065] R 3 is selected from optionally substituted C 1 -C 6 Alkyl, optionally substituted C 3 -C 6 cycloalkyl, optionally substituted aryl, and optionally substituted heteroaryl;
[0066] R 4 is H or optionally substituted C 1 -C 3 Alkyl, wherein the C 1 -C 3 The alkyl group is optionally attached to R 5 to form a ring;
[0067] R 5 is selected from optionally substituted C 1 -C 6 alkyl, optionally substituted aryl and optionally substituted heteroaryl, wherein R 5 Optionally connected to R 4 to form a ring;
[0068] R 6 is selected from optionally substituted aryl, optionally substituted heteroaryl, optionally substituted O-aryl or optionally substituted O-heteroaryl;
[0069] R 7 is selected from H, optionally substituted C 1 -C 6 Alkyl, CONR 10 R 11 、OCONR 10 R 11 ,OCOR 10 、OCOOR 10 、COOR 10 OR 12 ;
[0070] R 8 Selected from H, CONR 10 R 11 or COOR 10 ;
[0071] R 10 and R 11 are independently selected from H, optionally substituted C 1 -C 6Alkyl and optionally substituted C 2 -C 6 Alkyl, wherein the C 2 -C 6 Any one atom in the alkyl group is replaced by a heteroatom selected from N, O and S, or wherein R 10 and R 11 are optionally linked to form a ring; and
[0072] R 12 is optionally substituted aryl or optionally substituted heteroaryl.
[0073] W may be CH or N. W may be CH. W may be N.
[0074] X and Y can be CH 2 or O, wherein one of X and Y is CH 2 , and one of X and Y is O.
[0075] X can be CH 2 .X can be O.
[0076] Y can be CH 2 .Y can be O.
[0077] Z can be CHR 7 NR 8 or O. Z can be CHR 7 . Z can be NR 8 . Z can be O.
[0078] m can be 1 or 2. m can be 1. m can be 2.
[0079] n may be 0 to 3. n may be 0. n may be 1. n may be 2. n may be 3.
[0080] R 1 Each occurrence can be halogen, C 1 -C 3 Alkyl or C 1 -C 3 Alkoxy, where C 1 -C 3 Alkyl groups and C 1 -C 3 The alkoxy group is optionally substituted by up to 6 fluorine atoms. 1 It can be methoxy or methyl. 1 It may be a methoxy group. 1 It can be methyl. 1 It can be OMe or Me. 1 It can be OMe. 1 It can be Me.
[0081] q may be 0 to 2. q may be 0. q may be 1. q may be 2.
[0082] R 2 It may be H or C optionally substituted by up to 6 fluorine atoms. 1 -C 3 Alkyl. 2 It may be hydrogen. 2 It can be H. R 2 It can be methyl. 2 It can be Me.
[0083] R 3 It may be optionally substituted C 1 -C 6 Alkyl, optionally substituted C 3 -C 6 R is cycloalkyl, optionally substituted aryl or optionally substituted heteroaryl. 3 It may be optionally substituted C 1 -C 6 Alkyl, optionally substituted C 3 -C 6 Cycloalkyl or optionally substituted aryl, wherein the optional substituents are selected from halogen, C 1 -C 3 Alkyl and C 1 -C 3 Alkoxy, where C 1 -C 3 Alkyl groups and C 1 -C 3 The alkoxy group itself is optionally substituted by up to 6 fluorine atoms. 3 R may be optionally substituted phenyl, optionally substituted cyclohexyl, optionally substituted cyclopentyl or optionally substituted cyclobutyl, wherein the optional substituents are selected from chlorine, bromine and fluorine. 3 It may be phenyl which is optionally substituted by chlorine, bromine or fluorine. 3 It may be phenyl.
[0084] R 4 It can be H or optionally substituted C 1 -C 3 Alkyl, wherein the C 1 -C 3 The alkyl group is optionally attached to R 5 To form a ring. 4 It may be hydrogen. 4 It can be H. R 4 It may be optionally substituted C 1 -C 3 Alkyl.4 Can be C 1 -C 3 Alkyl. 4 Can be connected to R 5 to form a ring.
[0085] R 5 It may be optionally substituted C 1 -C 6 alkyl, optionally substituted aryl or optionally substituted heteroaryl, wherein R 5 Optionally connected to R 4 To form a ring. 5 It may be optionally substituted aryl or optionally substituted heteroaryl, wherein the optional substituents are selected from halogen, C 1 -C 3 Alkyl and C 1 -C 3 Alkoxy, where C 1 -C 3 Alkyl groups and C 1 -C 3 The alkoxy group itself is optionally substituted by up to 6 fluorine atoms. 5 R may be optionally substituted phenyl or optionally substituted pyridyl, wherein the optional substituent is selected from chlorine, bromine, fluorine and OMe. 5 It can be phenyl. 5 It may be pyridyl.
[0086] R 5 Can be connected to R 4 To form a ring. 4 and R 5 can be connected to form a ring selected from the group consisting of:
[0087]
[0088] wherein the ring moiety is optionally selected from halogen, C 1 -C 3 Alkyl and C 1 -C 3 substituted with one or more alkoxy groups, wherein the C 1 -C 3 Alkyl groups and C 1 -C 3 The alkoxy group itself is optionally substituted with up to 6 fluorine atoms;
[0089] R 6 R may be optionally substituted aryl, optionally substituted heteroaryl, optionally substituted O-aryl or optionally substituted O-heteroaryl. 6 It may be phenyl.
[0090] R 7 It can be H, optionally substituted C 1 -C 6 Alkyl, CONR 10 R 11 、OCONR 10 R 11 ,OCOR 10 、OCOOR 10 、COOR 10 OR 12 . R 7 It can be OCONR 10 R 11 、COOR 10 OR 12 ; where R 10 and R 11 It is C 2 -C 6 Alkyl, wherein the C 2 -C 6 Any one atom in the alkyl group is replaced by a heteroatom selected from N, O and S, wherein R 10 and R 11 Optionally via CH 2 Connect to form a ring.
[0091] R 7 Can be
[0092] R 7 Can be
[0093] R 7 Can be
[0094] R 8 Can be H, CONR 10 R 11 or COOR 10 . R 8 It may be hydrogen. 8 It can be H.
[0095] R 8 Can be
[0096] R 10 It can be H, optionally substituted C 1 -C 6 Alkyl or optionally substituted C 2 -C 6 Alkyl, where C 2 -C 6Any one atom in the alkyl group is replaced by a heteroatom selected from N, O and S. 10 It may be hydrogen. 10 It can be H. R 10 Can be -CH 2 CH 2 NH 2 .
[0097] R 11 It can be H, optionally substituted C 1 -C 6 Alkyl or optionally substituted C 2 -C 6 Alkyl, where C 2 -C 6 Any one atom in the alkyl group is replaced by a heteroatom selected from N, O and S. 11 It may be hydrogen. 11 It can be H. R 11 Can be -CH 2 CH 2 NH 2 .
[0098] R 10 and R 11 Can be connected to form a ring.
[0099] R 12 R may be an optionally substituted aryl group or an optionally substituted heteroaryl group. 12 It may be pyridyl.
[0100] The moiety formed by Z and m may be selected from:
[0101]
[0102] The part formed by Z and m can be
[0103]
[0104] The part formed by Z and m can be
[0105]
[0106] Specific compounds of the present invention also include compounds of formula (1a):
[0107]
[0108] or a salt thereof, wherein W, X, Y, Z, m, n, q, R 1 , R 2 , R 3 , R 4 , R 5and R 6 is as defined above.
[0109] Specific compounds of the present invention also include compounds of formula (1b):
[0110]
[0111] or a salt thereof, wherein W, Z, m, q, R 1 and R 3 is as defined above.
[0112] The compound can be selected from any one of Examples 1 to 79 shown in Table 1.
[0113] Specific examples of the compound include compounds having somatostatin receptor agonist activity.
[0114] Specific examples of compounds include those having SST 5 Receptor agonist activity.
[0115] Specific examples of compounds include 2 Receptor vs SST 5 Compounds that exhibit receptor selectivity.
[0116] The compounds of the present invention can be used in a pharmaceutical composition comprising the compounds of the present invention and a pharmaceutically acceptable excipient.
[0117] The compounds of the present invention can be used in medicine.
[0118] The compounds of the present invention can be used to treat disorders associated with somatostatin receptors.
[0119] The compounds of the present invention can be used to treat SST 5 Receptor-related disorders.
[0120] The compounds of the present invention can be used to treat Cushing's disease, Cushing's syndrome, acromegaly, neuroendocrine tumors (including carcinoid tumors), thyrotropinoma, prolactinoma, non-functioning pituitary adenoma, Nelson's syndrome, congenital hyperinsulinism, hypoglycemia after gastric bypass, dumping syndrome, hyperinsulinemic obesity, insulinoma, polycystic kidney disease, polycystic liver disease, portal hypertension, ascites, pancreatic cancer, pancreatic fistula, acute or chronic pancreatitis, hepatocellular carcinoma, irritable bowel syndrome / irritable bowel disease, headache disorders (including migraine, cluster headache, tension-type headache).
[0121] definition
[0122] In this application, the following definitions apply unless stated otherwise.
[0123] Unless otherwise indicated, the terms "alkyl," "aryl," "halogen," "alkoxy," "cycloalkyl," and "heteroaryl" are used in their conventional sense (eg, as defined in the IUPAC Gold Book).
[0124] With respect to the use of any compound described herein, including those of Formula (1), Formula (1a), or Formula (1b), the term "treatment" is used to describe any form of intervention in which a compound is administered to a subject suffering from, or at risk of, or potentially at risk of the disease or disorder in question. Thus, the term "treatment" encompasses both preventative (prophylactic) treatment and treatment in which measurable or detectable symptoms of a disease or disorder are exhibited.
[0125] As used herein, the term "therapeutically effective amount" (e.g., with respect to a method of treatment of a disorder, disease, or condition) refers to an amount of a compound effective to produce the desired therapeutic effect. For example, if the condition is pain, a therapeutically effective amount is an amount sufficient to provide a desired level of pain relief. The desired level of pain relief can be, for example, complete elimination of pain or a reduction in the severity of pain.
[0126] Insofar as any compound described has a chiral center, the present invention extends to all optical isomers of such compounds, whether in the form of racemates or resolved enantiomers. However, the invention described herein relates to all so prepared crystalline forms, solvates and hydrates of any disclosed compound. Insofar as any compound disclosed herein has an acidic center or a basic center such as a carboxylic acid group or an amino group, all salt forms of the compound are included herein. In the case of pharmaceutical use, the salt should be regarded as a pharmaceutically acceptable salt.
[0127] Salts or pharmaceutically acceptable salts that may be mentioned include acid addition salts and base addition salts. Such salts can be formed by conventional means, for example, by reacting the free acid form or free base form of the compound with one or more equivalents of a suitable acid or base, optionally in a solvent or in a medium in which the salt is insoluble, and then removing the solvent or medium using standard techniques (e.g., in a vacuum, by freeze drying or by filtering). The salt can also be prepared, for example, using a suitable ion exchange resin, by exchanging the counterion of the compound in salt form with another counterion.
[0128] Examples of pharmaceutically acceptable salts include acid addition salts derived from inorganic and organic acids, and salts derived from metals such as sodium, magnesium, potassium and calcium.
[0129] Examples of acid addition salts include acid addition salts formed with acetic acid, 2,2-dichloroacetic acid, adipic acid, alginic acid, arylsulfonic acids (e.g., benzenesulfonic acid, naphthalene-2-sulfonic acid, naphthalene-1,5-disulfonic acid, and p-toluenesulfonic acid), ascorbic acid (e.g., L-ascorbic acid), L-aspartic acid, benzoic acid, 4-acetamidobenzoic acid, butyric acid, (+)-camphoric acid, camphorsulfonic acid, (+)-(1S)-camphor-10-sulfonic acid, decanoic acid, hexanoic acid, octanoic acid, cinnamic acid, citric acid, cyclamic acid, dodecylsulfuric acid, ethane-1,2-disulfonic acid, ethanesulfonic acid, 2-hydroxyethanesulfonic acid, formic acid, fumaric acid, mucic acid, gentisic acid, glucoheptonic acid, gluconic acid (e.g., D-gluconic acid), glucuronic acid (e.g.,
[0013] Examples of the present invention include, but are not limited to, D-glucuronic acid), glutamic acid (e.g., L-glutamic acid), α-ketoglutaric acid, glycolic acid, hippuric acid, hydrobromic acid, hydrochloric acid, hydroiodic acid, isethionic acid, lactic acid (e.g., (+)-L-lactic acid and (±)-DL-lactic acid), lactobionic acid, maleic acid, malic acid (e.g., (-)-L-malic acid), malonic acid, (±)-DL-mandelic acid, metaphosphoric acid, methanesulfonic acid, 1-hydroxy-2-naphthoic acid, nicotinic acid, nitric acid, oleic acid, orotic acid, oxalic acid, palmitic acid, pamoic acid, phosphoric acid, propionic acid, L-pyroglutamic acid, salicylic acid, 4-amino-salicylic acid, sebacic acid, stearic acid, succinic acid, sulfuric acid, tannic acid, tartaric acid (e.g., (+)-L-tartaric acid), thiocyanic acid, undecylenic acid, and valeric acid.
[0130] Also contemplated are any solvates of these compounds and their salts. Preferred solvates are solvates formed by incorporating molecules of a non-toxic pharmaceutically acceptable solvent (hereinafter referred to as a solvating solvent) into the solid state structure (e.g., crystal structure) of the compounds of the invention. Examples of such solvents include water, alcohols (such as ethanol, isopropanol and butanol) and dimethyl sulfoxide. Solvates can be prepared by recrystallizing the compounds of the invention with a solvent or a solvent mixture containing the solvating solvent. Whether a solvate has been formed in any given case can be determined by subjecting the crystals of the compound to analysis using well-known and standard techniques such as thermogravimetric analysis (TGA), differential scanning calorimetry (DSC) and X-ray crystallography.
[0131] The solvate can be a stoichiometric or non-stoichiometric solvate. A specific solvate can be a hydrate, and examples of hydrates include hemihydrates, monohydrates, and dihydrates. For a more detailed discussion of solvates and methods for preparing and characterizing them, see Bryn et al., Solid-State Chemistry of Drugs, Second Edition, published by SSCI, Inc of West Lafayette, IN, USA, 1999, ISBN 0-967-06710-3.
[0132] In the context of the present invention, the term "pharmaceutical composition" means a composition comprising an active agent and additionally comprising one or more pharmaceutically acceptable carriers. Depending on the nature of the mode of administration and the dosage form, the composition may also comprise ingredients selected from, for example, diluents, adjuvants, excipients, vehicles, preservatives, fillers, disintegrants, wetting agents, emulsifiers, suspending agents, sweeteners, flavoring agents, perfuming agents, antibacterial agents, antifungal agents, lubricants and dispersants. The composition may take, for example, the following forms: tablets; dragees; powders; elixirs; syrups; liquid products, including suspensions, sprays, inhalants, tablets, lozenges, emulsions, solutions, cachets, granules, capsules and suppositories; and liquid products for injection, including liposomal products.
[0133] The compounds of the invention may contain one or more isotopic substitutions, and reference to a specific element includes within its scope all isotopes of that element. For example, reference to hydrogen would include 1 H. 2 H(D) and 3 H(T) is included within its scope. Similarly, references to carbon and oxygen will be 12 C. 13 C and 14 C and 16 O and 18 O is included in its scope. In a similar manner, unless the context indicates otherwise, mentioning a specific functional group also includes isotopic variations in its scope. For example, mentioning an alkyl group such as an ethyl group, or mentioning an alkoxy group such as a methoxy group, also includes a variation in which one or more hydrogen atoms in the group are in a deuterium or tritium isotopic form, for example, such as in an ethyl group in which all five hydrogen atoms are in a deuterium isotopic form (perdeuteroethyl group), or in a methoxy group in which all three hydrogen atoms are in a deuterium isotopic form (trideuteroethyl group). Isotopes can be radioactive or non-radioactive.
[0134] The therapeutic dose may vary depending on the patient's needs, the severity of the condition being treated, and the compound used. The determination of a dose suitable for a particular situation is within the skill of the art. Typically, treatment is initiated with a smaller dose that is less than the optimal dose of the compound. Thereafter, the dose is increased in small increments until the optimal effect in the situation is achieved. For convenience, the total daily dose may be divided and administered in portions during a day, if desired.
[0135] The size (magnitude) of the effective dose of the compound will certainly vary with the severity of the condition to be treated and with the specific compound and its route of administration. The selection of suitable dosage is within the ability of those of ordinary skill in the art, without excessive burden. Usually, the daily dosage range can be from about 10 μg to about 30 mg per kg of human body weight and non-human animal body weight, preferably from about 50 μg to about 30 mg per kg of human body weight and non-human animal body weight, for example, from about 50 μg to about 10 mg per kg of human body weight and non-human animal body weight, for example, from about 100 μg to about 30 mg per kg of human body weight and non-human animal body weight, for example, from about 100 μg to about 10 mg per kg of human body weight and non-human animal body weight, and most preferably from about 100 μg to about 1 mg per kg of human body weight and non-human animal body weight.
[0136] Pharmaceutical preparations
[0137] While it is possible for the active compound to be administered alone, it is preferable to present it as a pharmaceutical composition (eg, formulation).
[0138] Therefore, in another embodiment of the present invention, there is provided a pharmaceutical composition comprising at least one compound of formula (1) as defined above and at least one pharmaceutically acceptable excipient.
[0139] The composition may be a composition suitable for injection. The injection may be intravenous (IV) or subcutaneous. The composition may be provided in a sterile buffer solution or as a solid which may be suspended or dissolved in a sterile buffer for injection.
[0140] Pharmaceutically acceptable excipients can be selected from, for example, carriers (e.g., solid, liquid or semisolid carriers), adjuvants, diluents (e.g., solid diluents such as fillers or bulking agents; and liquid diluents such as solvents and co-solvents), granulating agents, binders, flow aids, coating agents, release controlling agents (e.g., release-delaying or release-retarding polymers or waxes), binding agents, disintegrants, buffers, lubricants, preservatives, antifungal and antibacterial agents, antioxidants, buffers, tonicity modifiers, thickeners, flavoring agents, sweeteners, pigments, plasticizers, taste-masking agents, stabilizers or any other excipients conventionally used in pharmaceutical compositions.
[0141] The term "pharmaceutically acceptable" as used herein means compounds, materials, compositions and / or dosage forms that are, within the scope of sound medical judgment, suitable for use in contact with the tissues of subjects (e.g., human subjects) without excessive toxicity, irritation, allergic response, or other problems or complications, commensurate with a reasonable benefit / risk ratio. Each excipient must also be "acceptable" in the sense of being compatible with the other ingredients of the formulation.
[0142] Pharmaceutical compositions comprising compounds of formula (1) can be formulated according to known techniques, see, for example, Remington's Pharmaceutical Sciences, Mack Publishing Company, Easton, PA, USA.
[0143] Suitable formulations typically contain 0%-20% (w / w) buffer, 0%-50% (w / w) cosolvent and / or 0%-99% (w / w) water for injection (WFI) (depending on the dose and whether lyophilized). Formulations for intramuscular depots may also contain 0%-99% (w / w) oil.
[0144] The compound of formula (1) will generally be presented in a unit dosage form and will therefore generally contain enough compound to provide the desired level of biological activity. For example, a formulation may contain from 1 nanogram to 2 grams of active ingredient, for example from 1 nanogram to 2 milligrams of active ingredient. Within these ranges, specific subranges of compound are 0.1 milligram to 2 grams of active ingredient (more typically from 10 milligrams to 1 gram, for example 50 milligrams to 500 milligrams), or 1 microgram to 20 milligrams (e.g. 1 microgram to 10 milligrams, for example 0.1 milligram to 2 milligrams of active ingredient).
[0145] The active compound will be administered to a patient (eg, a human patient or an animal patient) in need thereof in an amount sufficient to achieve the desired therapeutic effect (effective amount). The precise amount of compound administered can be determined by the supervising physician according to standard procedures. Example
[0146] The present invention will now be illustrated with reference to specific embodiments described in the following examples but the invention is not limited to said specific embodiments.
[0147] Example 1 to Example 79
[0148] The compounds of Example 1 to Example 79 shown in the following Table 1 have been prepared. The NMR properties and LCMS properties of these compounds and the methods used to prepare them are set forth in Table 2 and Table 3. The starting materials used in each example were commercially available unless otherwise specified.
[0149]
[0150]
[0151]
[0152]
[0153]
[0154]
[0155]
[0156]
[0157]
[0158] General Procedure
[0159] Where preparative routes are not included, the relevant intermediates are commercially available. Commercial reagents were used without further purification. Room temperature (rt) refers to about 20°C-27°C. The data were recorded at 600 MHz on a Bruker instrument. 1 H NMR spectra. Chemical shift values are expressed in parts per million (ppm), i.e. (δ) values. The following abbreviations are used for the multiplicity of NMR signals: s = singlet, br = broad, d = doublet, t = triplet, q = quartet, quint = quintet, td = triplet of doublet, tt = triplet of triplet, qd = quartet of doublet, ddd = doublet of doublet of doublet, ddt = doublet of doublet of triplet, m = multiplet. Coupling constants are listed as J values measured in Hz. NMR and mass spectrometry results were corrected to account for background peaks. Chromatography refers to column chromatography performed using 60-120 mesh silica gel and under nitrogen pressure (flash chromatography).
[0160] Analytical methods
[0161] LCMS analysis of compounds was performed under electrospray conditions.
[0162] LCMS Method A
[0163] Water Acquity UPLC-H grade, column: Waters BEH C18 1.7 μm, 2.1×50 mm. Gradient [time (min) / solvent B (%)]: 0.0 / 10, 0.5 / 10, 2.5 / 90, 3.0 / 90. (Solvent A-0.025% HCOOH in water; Solvent B-0.025% HCOOH in MeCN); injection volume 0.1 μL (can be varied); UV detection 210 nm; column temperature 30° C.; 0.3 mL / min.
[0164] Analytical Method B
[0165] MS ions were determined using the following LCMS method under electrospray conditions, and HPLC retention times (R T ) Purity by HPLC was >95% as determined using the HPLC method below unless otherwise stated.
[0166] LCMS: Water Acquity UPLC-H grade, column: Waters BEH C18 1.7 μm, 2.1×50 mm. Gradient [time (min) / solvent B (%)]: 0.0 / 10, 0.5 / 10, 2.5 / 90, 3.0 / 90. (Solvent A-0.025% HCOOH in water; Solvent B-0.025% HCOOH in MeCN); injection volume 0.1 μL (can be varied); UV detection 210 nm; column temperature 30° C.; 0.3 mL / min.
[0167] HPLC: Agilent Technologies 1200, Water SunFire C18, 3.5 μm, 4.6×150 mm, 30°C, 1 mL / min; mobile phase A: 0.025% TFA in water, mobile phase B: MeCN. a: gradient, 5%-75% (MeCN: H 2 O, 15 min), b: gradient, 10%-90% (MeCN:H 2 O, 15min); c: 20%-90% (MeCN: H 2 O, 15min).
[0168] Analytical Method C
[0169] MS ions were determined using the following LCMS method under electrospray conditions, and HPLC retention times (R T ) Purity by HPLC was >95% as determined using the HPLC method below unless otherwise stated.
[0170] LCMS: Agilent 1200HPLC & 6410B Triple Quad, Column: XbridgeC18 3.5um 2.1*30mm. Gradient [time (min) / solvent B (%)]: 0.0 / 10, 0.9 / 80, 1.5 / 90, 8.5 / 5, 1.51 / 10. (Solvent A = 1 mL of TFA in 1000 mL of water; Solvent B = 1 mL of TFA in 1000 mL of MeCN); injection volume 5 μL (can be varied); UV detection 220 nm 254 nm 210 nm; column temperature 25°C; 1.0 mL / min.
[0171] HPLC: Agilent Technologies 1200, column: Gemini-NX C18 5μm 110A150*4.6mm. Gradient [time (min) / solvent B (%)]: 0.0 / 30, 20 / 60, 20.1 / 90, 23 / 90. (Solvent A = 1 mL of TFA in 1000 mL of water; Solvent B = 1 mL of TFA in 1000 mL of MeCN); injection volume 5μL (can be varied); UV detection 220nm 254nm; column temperature 25°C; 1.0mL / min.
[0172] Analytical Method D
[0173] Instrument: Thermo Scientific Orbitrap Fusion; Column: Phenomenex Kinetex Biphenyl 2.6μm, 2.1x 50mm; Gradient [time (min) / solvent B in A (%)]: 0.00 / 10, 0.30 / 10, 0.40 / 60, 1.10 / 90, 1.70 / 90, 1.75 / 10, 1.99 / 10, 2.00 / 10; Solvent: Solvent A = 0.1% formic acid in water; Solvent B = 0.1% formic acid in acetonitrile; Injection volume 5μL; Column temperature 25℃; Flow rate 0.8mL / min.
[0174] Synthesis of intermediates
[0175] Synthesis of Fmoc-D-Trp(4-Me)
[0176]
[0177] program
[0178] N-Boc-4-methylindole (1)
[0179] 4-Methylindole (5.0 g, 38 mmol) and dimethylaminopyridine (1.04 g, 8.54 mmol) were dissolved in acetonitrile (60 mL), and then a solution of di-tert-butyl dicarbonate (14.0 g, 64 mmol) in acetonitrile (10 mL) was slowly added. The reaction was stirred at N 2 Stirring was continued at room temperature for 18 h under an atmosphere of sodium bicarbonate and then concentrated. The residue was diluted with EtOAc (100 mL) and washed with 1N HCl (100 mL×3), saturated NaHCO 3 (100 mL x 3), water (100 mL x 1) and brine (100 mL x 1), and then dried (MgSO 4 ). After filtration, the solvent was removed to provide compound 1 (8.3 g, quantitative yield), which was used in the next step without further purification.
[0180] N-Boc-3-bromo-4-methylindole (2)
[0181] N-Bromosuccinimide (8.3 g, 47 mmol) was added all at once to a solution of N-Boc-indole (8.3 g, 38 mmol) in THF (100 mL), and the reaction was stirred at room temperature for 18 h. The reaction mixture was concentrated, and the residue was diluted with EtOAc (100 mL), saturated aqueous sodium metabisulfite (100 mL×3), saturated aqueous NaHCO 3 (100 mL × 3) and washed with brine. The organic phase was dried (MgSO 4 ) and concentrated to provide compound 2 (8.7 g, yield 74%) as a yellow oil.
[0182] (S)-2-(tert-Butyloxycarbonylamino)-3-iodopropionic acid methyl ester (3)
[0183] The mixture of triphenylphosphine (131g, 0.50mol) and imidazoles (34g, 0.50mol) in DCM (600mL) is cooled to 0 DEG C, and iodine (127g, 0.50mol) is added in small portions in 0.5h. Remove cooling bath and stir the mixture for 0.5h. After the mixture is cooled to 0 DEG C again, a solution of compound 2 (73g, 0.33mol) in DCM (300mL) is added dropwise. After completion, remove cooling bath, and allow the mixture to warm up to room temperature and stir for 1.5h. Filter the mixture, and concentrate the filtrate to remove most of solvent. Add MTBE (400mL) to residue, and filter the mixture to remove triphenylphosphine oxide. Concentrate the filtrate, and residue is purified by flash column chromatography to provide 3 (74.0g, 68% yield) as a yellow solid.
[0184] (R)-3-(2-(tert-Butyloxycarbonylamino)-3-methoxy-3-oxopropyl)-4-methyl-1H-indole-1-carboxylate Tert-Butyl Acid Ester (4)
[0185] A solution of compound 3 (7.5 g, 26 mmol) and iodine (0.5 g) in DMF (30 mL) was added to a suspension of zinc (4.5 g, 77 mmol) in DMF (50 mL). The mixture was stirred at 30 ° C for 30 min under nitrogen and then cooled to room temperature. Compound 2 (8.0 g, 25.8 mol), S-Phos (200 mg) and Pd (dba) were added. 2 The reaction mixture was stirred at 50 ° C overnight under nitrogen and then cooled to room temperature. Brine (500 mL) was added and the resulting mixture was extracted with EtOAc (300 mL×3). The organics were combined, washed with brine and concentrated. The residue was purified by flash column chromatography (petroleum ether / ethyl acetate=100:1 to 40:1) to provide 4 (3.3 g, 30% yield) as a viscous oil.
[0186] D-Trp(4-Me)-OH(5)
[0187] To a solution of compound 4 (3.3 g, 7.6 mmol) in a mixture of water / methanol (30 mL, 2: 1) was added lithium hydroxide hydrate (1.3 g, 30 mmol). The reaction mixture was stirred at room temperature for 3 h, and then concentrated to remove most of the methanol. The residue was extracted with EtOAc (30 mL × 3), washed with brine (20 mL × 2), dried and concentrated to provide an acid.
[0188] The above acid was dissolved in DCM (20 mL) and TFA (5 mL) was added. The reaction mixture was stirred for 1 h and then concentrated to afford 5 as a TFA salt which was used in the next step without further purification.
[0189] Fmoc-D-Trp(4-Me)
[0190] Compound 5 (7.6 mmol) was dissolved in acetone (100 mL) and saturated aqueous NaHCO 3 (100 mL) was added to the mixture. Fmoc-OSu (2.5 g, 7.5 mmol) was added. The reaction mixture was stirred at room temperature for 18 h. The reaction was heated to 40 °C with H 2 O (100 mL), washed with hexane (100 mL × 2). The aqueous phase was acidified to pH 3 with 1N HCl and extracted with EtOAc (100 mL × 3). The combined EtOAc phase was washed with 1N HCl (100 mL × 3) and brine (100 mL × 1), and then filtered through MgSO 4After filtration, the solvent was removed by concentration, and the residue was purified by flash column chromatography (DCM / MeOH=100:1 to 20:1) to afford Fmoc-D-Trp(4-Me) (2.3 g, 68% yield of compound 4) as a white solid.
[0191] LCMS (method A): m / z 441.7 [M+H] + (ES+)
[0192] The following compounds were synthesized using the same method:
[0193]
[0194] Synthesis of Fmoc-Tyr(O-cyclohexylmethyl)
[0195]
[0196] program
[0197] Fmoc-L-Tyr(O-cyclohexylmethyl)-OMe(1)
[0198] A mixture of Fmoc-Tyr-OMe (1.5 g, 3.6 mmol), cyclohexylmethanol (500 mg, 4.4 mmol) and triphenylphosphine (1.13 g, 4.3 mol) in THF (100 mL) was cooled to 0 ° C, and DEAD (800 mg, 4.3 mol) was added. The mixture was allowed to warm to room temperature and stirred overnight. The reaction mixture was concentrated, and the residue was purified by flash column chromatography to provide compound 1 (0.9 g, 48% yield).
[0199] Fmoc-L-Tyr(O-cyclohexylmethyl)
[0200] To a solution of compound 1 (0.9 g, 1.7 mmol) in water / methanol (30 mL, 10: 1) was added lithium hydroxide hydrate (100 mg, 2.4 mmol). The reaction mixture was stirred at 0 ° C for 3 h and then acidified to pH 3 with 1N HCl. The mixture was then extracted with EtOAc (30 mL×3), the extract was washed with brine (20 mL×2), dried and concentrated. The residue was purified by flash column chromatography (DCM / MeOH=100: 1 to 20: 1) to provide Fmoc-L-Tyr (O-cyclohexylmethyl) (630 mg, 74% yield) as a white solid.
[0201] LCMS (Method A): m / z 500.9 [M+H] + (ES+)
[0202] The following compounds were synthesized using the same method:
[0203]
[0204] Synthesis of Cyclohexapeptide Examples 1-79
[0205] Standard Fmoc solid phase peptide synthesis (SPPS) is used to synthesize linear peptides, which are then cleaved and cyclized from the resin to give cyclohexyl peptides. This linear synthesis can start at any position of the 6-mer sequence and can then be cyclized to give the final cyclohexyl peptide, and two methods are outlined below.
[0206] Method a
[0207] Peptide synthesis
[0208] 1) Add CTC-resin (0.4 mmol) and Fmoc-trans-4-HYP-OH (282.7 mg, 0.8 mmol, 2.0 equiv) to a vessel under bubbling N 2 (g) was added DCM (10 mL).
[0209] 2) DIEA (263.9 μL, 1.6 mmol, 4.0 equiv) was added dropwise, and the reaction was stirred for 2 h.
[0210] 3) MeOH (0.8 mL) was added and the reaction was stirred for 30 min.
[0211] 4) The resin was drained and washed with DMF (x 5).
[0212] 5) Bis(p-nitrophenyl) carbonate (730.0 mg, 2.4 mmol, 6.0 equiv) and DIEA (0.8 mL, 4.8 mmol, 12.0 equiv) were added to the vessel and the reaction was continued for 4 h. After the reaction was complete, the resin was washed with DMF (x5).
[0213] 6) N-Boc-ethylenediamine (770.0 mg, 4.8 mmol, 12.0 equiv) and DIEA (0.8 mL, 4.8 mmol, 12.0 equiv) were added separately to the resin in DMF (10 mL). The reaction was mixed at room temperature overnight.
[0214] 7) The resin was drained and washed with DMF (x 5).
[0215] 8) A solution of piperidine in DMF (piperidine:DMF, 1:4) was added and the reaction was continued for 30 min.
[0216] 9) The resin was drained and washed with DMF (x 5).
[0217] 10) Add Fmoc-amino acid solution (0.8 mmol, 2.0 eq) to the resin and mix for 30 seconds, followed by HATU (2.0 eq) and DIEA (4.0 eq). 2 (g) Bubble through the mixture for 1 h.
[0218] 11) The resin was drained and washed with DMF (x 5).
[0219] 12) Repeat steps 8 to 11 for the next amino acid coupling.
[0220] Peptide cleavage, cyclization and purification
[0221] 1) To the flask containing the side-chain protected peptide was added lysis buffer (1% TFA in DCM, 10 mL) at rt, and the resulting mixture was stirred for 0.5 h.
[0222] 2) The reaction mixture was filtered and the filtrate was diluted to 1 mM with anhydrous DCM. DIEA was added to adjust the pH to 8. TBTU (385.2 mg, 1.2 mmol, 3.0 eq.) and HOBT (162.9 mg, 1.2 mmol, 3.0 eq.) were added to the solution and the resulting solution was reacted for 3-4 h.
[0223] 3) After completion, the reaction mixture was washed with 1N HCl (200 mL) and the organic phase was dried under vacuum to obtain the crude peptide which was purified by HPLC with TFA:H 2 O:TIPS 95:2.5:2.5 Further treatment lasts for 10 min-1 h.
[0224] 4) The crude peptide was precipitated by adding methyl tert-butyl ether.
[0225] 5) The crude peptide was purified by HPLC to give the final product. Preparative-HPLC conditions: Instrument: Gilson 281. Solvent: A-0.1% TFA in H 2 O, B-acetonitrile, column: luna C18 (200×25 mm; 10 μm) and Gemini C18 (150*30 mm; 5 μm) connected in series. Gradient [time (min) / solvent B (%)]: 0.0 / 25, 60.0 / 55, 60.1 / 90, 70 / 90, 70.1 / 10, for example 17.
[0226] Method b
[0227] Peptide synthesis
[0228] 1) CTC-resin (1 eq) was swelled in DMF (10×) for 2 h, washed three times with DMF (10×), three times with DCM (10×), and three times with DMF (10×).
[0229] 2) The Fmoc-protected amino acid (3 eq) was dissolved in DMF, and then DIC (2.9 eq), HOBt (2.9 eq) and NMM (5.6 eq) were added. The resulting mixture was shaken for 1 min and transferred to the resin.
[0230] 3) The reaction was shaken for 1 h-2 h and monitored by the Kaiser method.
[0231] 4) After coupling, the resin was washed with DMF.
[0232] 5) The Fmoc group was removed twice (2 min, 8 min) using a solution of piperidine in DMF (piperidine:DMF, 1:4).
[0233] 6) The resin was carefully washed three times with DMF (10x), three times with DCM (10x), and three times with DMF (10x).
[0234] Note: Fmoc-phenylglycine was converted to its activated HOBt-ester [freshly prepared from Fmoc-Phg (3.0 equiv) and HOBt (3.0 equiv) in the presence of DIC (3.0 equiv, 0 °C, 20 min) before solid phase synthesis].
[0235] Peptide cleavage, cyclization and purification
[0236] 1) The full-length linear peptide was cleaved from the resin by swelling and shaking the peptide resin in 1:1 (v:v) TFE / DCM (10 vol / g dry resin) for 4 h.
[0237] 2) The cleaved solution was filtered and the drained resin was washed with additional DCM (5 vol / g of initially dried peptide resin) to completely extract the cleaved peptide from the resin. The solvent in the combined filtrates was evaporated and the residue was dried.
[0238] 3) The crude peptide was dissolved in a mixture of DMF / DCM (30 vol / g, 1 / 5), cooled to 0°C and DIC (5 eq) and HOBt (5 eq) were added. After completion, the reaction was heated with aqueous saturated NaCO 3 The organic layer was dried, filtered and concentrated to provide the crude cyclic peptide.
[0239] 4) The crude cyclic peptide was deprotected by stirring in a mixture of TFA / DCM (50 volumes / g, 1 / 1) for 1 h. The product was precipitated from cold ether and filtered to provide a crude peptide, which was purified by preparative-HPLC to provide a cyclohexyl peptide. Preparative-HPLC conditions: Instrument: Water Auto-P2545 / 2489 / 515. Solvent: A-0.1% TFA in water, B-MeCN, Column: SunFire Preparative C18 OBD, 5μm, 30×100mm. Gradient [time (min) / solvent B (%)]: 0.0 / 30, 1.0 / 30, 9.0 / 45, 9.5 / 95, 13.0 / 95. UV detection 210nm & MS detection; column temperature 25°C; 30mL / min.
[0240] Table 2 - HRMS and LCMS properties and methods used to prepare and purify the peptides represented by Examples 1 to 79
[0241]
[0242]
[0243]
[0244]
[0245]
[0246]
[0247] ND - Not Determined
[0248]
[0249]
[0250]
[0251]
[0252]
[0253]
[0254]
[0255] Biological activity
[0256] use cAMP XS+ assay to monitor SST via Gi G proteins 2and SST 5 Cells were pre-stimulated with forskolin to elicit a cAMP response, and the potency and efficacy of somatostatin agonists to reduce cAMP were measured. Briefly, cells (10,000 cells / well) were cultured in culture medium (2:1 HBSS / 10 mM Hepes:cAMP XS+Ab reagent), in EC 80 Forskolin (20 μM SST 2 and 15 μM SST 5 ) were incubated with compounds (10 μM-10 fM) in the presence of 20 μL cAMP XS+ED / CL lysis cocktail (60 min; RT).
[0257] The signal was then detected by incubation with 20 μL cAMP XS+EA reagent (180 min; RT). The microplate was used with PerkinElmer Envision TM Compound activity was normalized to that of somatostatin 28 (0% basal, 100% = signal obtained with 50 nM somatostatin 28) and data were analyzed using Dotmatics Browser using a 4-parameter logistic fit to determine potency (pEC 50 ) and efficacy (%).
[0258]
[0259]
[0260] The present application provides the following: 1) a compound of formula (1):
[0261]
[0262] or a salt thereof, wherein:
[0263] W is CH or N;
[0264] X and Y are CH 2 or O, wherein one of X and Y is CH 2 and the other of X and Y is O;
[0265] Z is for CHR 7 NR 8 or O;
[0266] m is 1 or 2;
[0267] n is 0 to 3;
[0268] Each R 1 independently selected from halogen, C 1 -C 3 Alkyl and C 1 -C 3 Alkoxy, wherein the C 1 -C 3 Alkyl groups and C 1 -C 3 The alkoxy group is optionally substituted with up to 6 fluorine atoms;
[0269] q is 0 to 2;
[0270] R 2 is selected from H and C optionally substituted by up to 6 fluorine atoms 1 -C 3 alkyl;
[0271] R 3 is selected from optionally substituted C 1 -C 6 Alkyl, optionally substituted C 3 -C 6 cycloalkyl, optionally substituted aryl, and optionally substituted heteroaryl;
[0272] R 4 is H or optionally substituted C 1 -C 3 Alkyl, wherein the C 1 -C 3 The alkyl group is optionally attached to R 5 to form a ring;
[0273] R 5 is selected from optionally substituted C 1 -C 6 alkyl, optionally substituted aryl and optionally substituted heteroaryl, wherein R 5 Optionally connected to R 4 to form a ring;
[0274] R 6 is selected from optionally substituted aryl, optionally substituted heteroaryl, optionally substituted O-aryl or optionally substituted O-heteroaryl;
[0275] R 7 is selected from H, optionally substituted C 1 -C 6 Alkyl, CONR 10 R 11 、OCONR 10 R 11 ,OCOR 10 、OCOOR 10、COOR 10 OR 12 ;
[0276] R 8 Selected from H, CONR 10 R 11 or COOR 10 ;
[0277] R 10 and R 11 are independently selected from H, optionally substituted C 1 -C 6 Alkyl and optionally substituted C 2 -C 6 Alkyl, wherein the C 2 -C 6 Any one atom in the alkyl group is replaced by a heteroatom selected from N, O and S, or wherein R 10 and R 11 are optionally linked to form a ring; and
[0278] R 12 is optionally substituted aryl or optionally substituted heteroaryl.
[0279] 2) The compound according to 1), which is a compound of formula (1a):
[0280]
[0281] or a salt thereof, wherein W, X, Y, Z, m, n, q, R 1 , R 2 , R 3 , R 4 , R 5 and R 6 It is defined according to 1).
[0282] 3) The compound according to 1), which is a compound of formula (1b):
[0283]
[0284] or a salt thereof, wherein W, Z, m, q, R 1 and R 3 It is defined according to 1).
[0285] 4) The compound according to any one of 1) to 3), wherein W is CH.
[0286] 5) The compound according to any one of 1) to 3), wherein W is N.
[0287] 6) The compound according to 1) or 2), wherein X is O and Y is CH 2 .
[0288] 7) A compound according to any one of 1) to 6), wherein Z is CHR 7 .
[0289] 8) A compound according to any one of 1) to 7), wherein R 1 It is OMe or Me.
[0290] 9) The compound according to 1) or 2), wherein R 2 It's H.
[0291] 10) A compound according to any one of 1) to 9), wherein R 3 is optionally substituted C 1 -C 6 Alkyl, optionally substituted C 3 -C 6 Cycloalkyl or optionally substituted aryl, wherein the optional substituents are selected from halogen, C 1 -C 3 Alkyl and C 1 -C 3 Alkoxy, wherein the C 1 -C 3 Alkyl groups and C 1 -C 3 The alkoxy group itself is optionally substituted with up to 6 fluorine atoms.
[0292] 11) The compound according to 10), wherein R 3 is optionally substituted phenyl, optionally substituted cyclohexyl, optionally substituted cyclopentyl or optionally substituted cyclobutyl, wherein the optional substituents are selected from chlorine, bromine and fluorine.
[0293] 12) The compound according to 1) or 2), wherein R 4 It's H.
[0294] 13) The compound according to 1) or 2), wherein R 5 is optionally substituted aryl or optionally substituted heteroaryl, wherein the optional substituents are selected from halogen, C 1 -C 3 Alkyl and C 1 -C 3 Alkoxy, wherein the C 1 -C 3 Alkyl groups and C 1 -C 3 The alkoxy group itself is optionally substituted with up to 6 fluorine atoms.
[0295] 14) The compound according to 13), wherein R 5 is optionally substituted phenyl or optionally substituted pyridinyl, wherein the optional substituents are selected from chloro, bromo, fluoro and OMe.
[0296] 15) The compound according to 1) or 2), wherein R 4 and R 5 Connect together to form a ring.
[0297] 16) The compound according to 15), wherein R 4 and R 5 The ring portion formed is selected from the group consisting of:
[0298]
[0299] wherein the ring moiety is optionally selected from halogen, C 1 -C 3 Alkyl and C 1 -C 3 substituted with one or more alkoxy groups, wherein the C 1 -C 3 Alkyl groups and C 1 -C 3 The alkoxy group itself is optionally substituted with up to 6 fluorine atoms.
[0300] 17) A compound according to any one of 1) to 16), wherein R 7 OCONR 10 R 11 、COOR 10 OR 12 ; where R 10 and R 11 It is C 2 -C 6 Alkyl, wherein the C 2 -C 6 Any one atom in the alkyl group is replaced by a heteroatom selected from N, O and S, wherein R 10 and R 11 Optionally via CH 2 connected to form a ring; and R 12 It is pyridyl.
[0301] 18) A compound according to any one of 1) to 3), wherein the moiety formed by Z and m is selected from:
[0302]
[0303] 19) The compound according to 1) or 2), wherein R 6 It is phenyl.
[0304] 20) The compound according to 1), which is selected from the group consisting of:
[0305]
[0306]
[0307]
[0308]
[0309]
[0310]
[0311]
[0312]
[0313]
[0314]
[0315]
[0316] 21) The compound according to 1), which is selected from the group consisting of:
[0317]
[0318] 22) The compound according to any one of 1) to 21), having SST 5 Receptor agonist activity.
[0319] 23) The compound according to 22), wherein the compound is treated with SST 2 Compared with the receptor, the compounds have an effect on SST 5 The receptors exhibit selectivity.
[0320] 24) A pharmaceutical composition comprising a compound as defined in any one of 1) to 23) and a pharmaceutically acceptable excipient.
[0321] 25) A compound or composition according to any one of 1) to 24) for use in the treatment of Cushing's disease, Cushing's syndrome, acromegaly, neuroendocrine tumors (including carcinoid tumors), thyrotropinomas, prolactinomas, non-functioning pituitary adenomas, Nelson's syndrome, congenital hyperinsulinemia, hypoglycemia after gastric bypass, dumping syndrome, hyperinsulinemic obesity, insulinoma, polycystic kidney disease, polycystic liver disease, portal hypertension, ascites, pancreatic cancer, pancreatic fistula, acute or chronic pancreatitis, hepatocellular carcinoma, irritable bowel syndrome / irritable bowel disease or headache disorders (including migraine, cluster headache, tension-type headache).
Claims
1. A compound of formula (1a): or a salt thereof, in: (i) Z is CHR 7 NR 8 or O; and m is 1 or 2; and / or (ii) the moiety formed by Z and m is selected from: And among them: W is CH or N; X and Y are CH 2 or O, wherein one of X and Y is CH 2 and the other of X and Y is O; n is 0 to 3; Each R 1 independently selected from halogen, C 1 -C 3 Alkyl and C 1 -C 3 Alkoxy, wherein the C 1 -C 3 Alkyl groups and C 1 -C 3 The alkoxy group is optionally substituted with up to 6 fluorine atoms; q is 0 to 2; R 2 is selected from H and C optionally substituted by up to 6 fluorine atoms 1 -C 3 alkyl; R 3 is selected from optionally substituted C 1 -C 6 Alkyl, optionally substituted C 3 -C 6 Cycloalkyl and optionally substituted aryl, wherein the optional substituents are selected from halogen, C 1 -C 3 Alkyl and C 1 -C 3 Alkoxy, wherein the C 1 -C 3 Alkyl groups and C 1 -C 3 The alkoxy group itself is optionally substituted with up to 6 fluorine atoms; R 4 Is H or C 1 -C 3 Alkyl, wherein the C 1 -C 3 The alkyl group is optionally attached to R 5 to form a ring; R 5 is selected from optionally substituted aryl or optionally substituted heteroaryl, wherein the optional substituents are selected from halogen, C 1 -C 3 Alkyl and C 1 -C 3 Alkoxy, wherein the C 1 -C 3 Alkyl groups and C 1 -C 3 The alkoxy group itself is optionally substituted by up to 6 fluorine atoms, or wherein R 5 Connect to R 4 to form a ring; R 6 is an aromatic group; R 7 Selected from H, C 1 -C 6 Alkyl, CONR 10 R 11 、OCONR 10 R 11 ,OCOR 10 、OCOOR 10 、COOR 10 OR 12 ; R 8 Selected from H, CONR 10 R 11 or COOR 10 ; R 10 and R 11 Independently selected from H, C 1 -C 6 Alkyl and C 2 -C 6 Alkyl, wherein the C 2 -C 6 Any one atom in the alkyl group is replaced by a heteroatom selected from N, O and S, or wherein R 10 and R 11 are optionally linked to form a ring; and R 12 is aryl or heteroaryl; When R 4 and R 5 When connected to form a ring, R 4 and R 5 The ring portion formed is selected from the group consisting of: wherein the ring moiety is optionally selected from halogen, C 1 -C 3 Alkyl and C 1 -C 3 substituted with one or more alkoxy groups, wherein the C 1 -C 3 Alkyl groups and C 1 -C 3 The alkoxy group itself is optionally substituted with up to 6 fluorine atoms.
2. The compound according to claim 1, which is a compound of formula (1b): or a salt thereof, wherein W, Z, m, q, R 1 and R 3 As defined in claim 1.
3. A compound according to claim 1 or claim 2, wherein W is CH.
4. A compound according to claim 1 or claim 2, wherein W is N.
5. A compound according to claim 1 or claim 2, wherein X is O and Y is CH 2 .
6. The compound according to claim 1 or claim 2, wherein Z is CHR 7 .
7. The compound according to claim 1 or claim 2, wherein R 1 It is OMe or Me.
8. The compound according to claim 1 or claim 2, wherein R 2 It's H.
9. The compound according to claim 1 or claim 2, wherein R 3 is optionally substituted phenyl, optionally substituted cyclohexyl, optionally substituted cyclopentyl or optionally substituted cyclobutyl, wherein the optional substituents are selected from chlorine, bromine and fluorine.
10. The compound according to claim 1 or claim 2, wherein R 4 It's H.
11. The compound according to claim 1 or claim 2, wherein R 5 is optionally substituted aryl or optionally substituted heteroaryl, wherein the optional substituents are selected from halogen, C 1 -C 3 Alkyl and C 1 -C 3 Alkoxy, wherein the C 1 -C 3 Alkyl groups and C 1 -C 3 The alkoxy group itself is optionally substituted with up to 6 fluorine atoms.
12. The compound according to claim 11, wherein R 5 is optionally substituted phenyl or optionally substituted pyridinyl, wherein the optional substituents are selected from chloro, bromo, fluoro and OMe.
13. The compound according to claim 1 or claim 2, wherein R 4 and R 5 connected together to form a ring, where R 4 and R 5 The ring portion formed is selected from the group consisting of: wherein the ring moiety is optionally selected from halogen, C 1 -C 3 Alkyl and C 1 -C 3 substituted with one or more alkoxy groups, wherein the C 1 -C 3 Alkyl groups and C 1 -C 3 The alkoxy group itself is optionally substituted with up to 6 fluorine atoms.
14. The compound according to claim 1 or claim 2, wherein R 7 OCONR 10 R 11 、COOR 10 OR 12 ; where R 10 and R 11 It is C 2 -C 6 Alkyl, wherein the C 2 -C 6 Any one atom in the alkyl group is replaced by a heteroatom selected from N, O and S, wherein R 10 and R 11 Optionally via CH 2 connected to form a ring; and R 12 It is pyridyl.
15. The compound according to claim 1 or claim 2, wherein the moiety formed by Z and m is selected from:
16. The compound according to claim 1 or claim 2, wherein R 6 It is phenyl.
17. The compound according to claim 1 or claim 2, having SST 5 Receptor agonist activity.
18. The compound according to claim 17, with SST 2 Compared with the receptor, the compounds have an effect on SST 5 The receptors exhibit selectivity.
19. A compound selected from the group consisting of: or a salt thereof.
20. A compound selected from the group consisting of: or a salt thereof.
21. The compound according to claim 20, selected from the group consisting of: or a salt thereof.
22. A pharmaceutical composition comprising a compound as defined in any one of claims 1 to 21 and a pharmaceutically acceptable excipient.
23. Use of a compound according to any one of claims 1 to 21 or a pharmaceutical composition according to claim 22 for the preparation of a medicament for treating Cushing's syndrome, acromegaly, neuroendocrine tumors, thyrotropinomas, prolactinomas, non-functioning pituitary adenomas, Nelson's syndrome, congenital hyperinsulinemia, hypoglycemia after gastric bypass, dumping syndrome, hyperinsulinemic obesity, insulinomas, polycystic kidney disease, polycystic liver disease, portal hypertension, ascites, pancreatic cancer, pancreatic fistula, acute or chronic pancreatitis, hepatocellular carcinoma, irritable bowel syndrome or headache disorders.
24. Use according to claim 23, wherein the neuroendocrine tumor is a carcinoid tumor.
25. The use according to claim 23, wherein the headache disorder is selected from migraine, cluster headache and tension-type headache.
26. Use of a compound according to any one of claims 1 to 21 or a pharmaceutical composition according to claim 22 for the preparation of a medicament for the treatment of Cushing's disease.
